FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders

Citation
D. Delbeke et al., FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders, J NUCL MED, 40(1), 1999, pp. 110-117
Citations number
27
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF NUCLEAR MEDICINE
ISSN journal
01615505 → ACNP
Volume
40
Issue
1
Year of publication
1999
Pages
110 - 117
Database
ISI
SICI code
0161-5505(199901)40:1<110:FPADGC>2.0.ZU;2-C
Abstract
The purpose of the study was to compare the diagnostic accuracy of fluorode oxyglucose (FDG) images obtained with a dual-head coincidence gamma camera (DHC) with those obtained with a dedicated PET in a series of 26 patients. Methods: Nineteen patients with known or suspected malignancies and 7 patie nts with neurological disorders underwent PET imaging after injection of ap proximately 10 mCi of FDG. Whole-body imaging was performed on 19 patients and brain imaging on 7 patients. DHC images were then acquired for 30 min o ver the region of interest using a dual-head gamma camera equipped with 3/8 -in.-thick Nal(TI) crystals and parallel slit-hole collimators. The images were reconstructed in the normal mode, using photopeak/photopeak, photopeak /Compton and Compton/photopeak coincidence events. Results: Although the sp atial resolutions of PET with a dedicated PET scanner and of DHC are in the same range, the lesion detectability remains superior with PET (4 mm for P ET versus 13.5 mm for DHC in phantom experiments) with a contrast ratio of 5:1. This is most probably attributable to the higher sensitivity of PET (2 238 coincidences/min/mu Ci for PET versus 89 coincidences/min/mu Ci for DHC ). The pattern of uptake and interpretation for brain imaging was similar o n both PET and DHC images in ail patients. In the 19 oncology patients, 38 lesions ranging from 0.7 to 5 cm were detected by PET. DHC imaging detected 28 (73%) Of these lesions. Among the 10 lesions not seen with DHC, 5 were less than 1.2 cm, 2 were located centrally within the liver and suffered fr om marked attenuation effects and 3 were adjacent to regions with high phys iological activity. The nondetectability of some lesions with DHC compared with PET can be explained by several factors: (a) start of imaging time (me an +/- SD: 73 +/- 16 min for PET versus 115 +/- 68 min for DHC, leading to FDG decay to 6.75 mCi for PET and 5.2 mCi for DHC); (b) limited efficiency of a 3/8-inch-thick Nal(Ti) crystal to detect F-18 photons; (c) suboptimal two-dimensional reconstruction algorithm; and (d) absence of soft-tissue at tenuation correction for centrally located lesions. Conclusion: FDG DHC ima ging is a promising technique for oncological and brain imaging.